Mediwound Ltd. cash flow statement
In fiscal 2025, Mediwound Ltd.'s operations generated −$16.1m of cash; it spent $5.5m on capital projects, leaving free cash flow of −$21.6m.
Cash flow statement
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −20 | −16 | −16 | −12 | 8 | −7 | −9 | −12 | −10 | −14 | −16 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 |
| Stock-based pay | 3 | 3 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 |
| Capital spending | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 6 | 6 | 6 |
| Free cash flow | −20 | −17 | −18 | −13 | 7 | −8 | −9 | −12 | −17 | −20 | −22 |
| Free cash flow after stock pay | −23 | −20 | −19 | −13 | 6 | −9 | −11 | −14 | −19 | −23 | −25 |
Compare with peers
- Proqr Therapeutics N.V. cash flow
- Cytomx Therapeutics, Inc. cash flow
- Celularity Inc cash flow
- Scynexis Inc cash flow
- Keros Therapeutics, Inc. cash flow
Head to head: MDWD vs PRQRCTMX vs MDWDCELU vs MDWD
More: Biotechnology stocks compared, Health Care sector, rankings of US companies